An open-label, Phase I/II study to assess the safety and clinical activity of NKR-2 treatment administration after non-myeloablative preconditioning chemotherapy in relapse/refractory acute myeloid leukemia or myelodysplasic syndrome patient (DEPLETHINK -

×

Message d'erreur

  • Notice : Trying to access array offset on value of type null dans bootstrap_pager() (ligne 53 dans /var/www/biosafety.be/sites/all/themes/bootstrap/templates/system/pager.func.php).
  • Notice : Trying to access array offset on value of type null dans bootstrap_pager() (ligne 95 dans /var/www/biosafety.be/sites/all/themes/bootstrap/templates/system/pager.func.php).
Study title: 
An open-label, Phase I/II study to assess the safety and clinical activity of NKR-2 treatment administration after non-myeloablative preconditioning chemotherapy in relapse/refractory acute myeloid leukemia or myelodysplasic syndrome patient (DEPLETHINK -
Long title: 
An open-label, Phase I/II study to assess the safety and clinical activity of NKR-2 treatment administration after non-myeloablative preconditioning chemotherapy in relapse/refractory acute myeloid leukemia or myelodysplasic syndrome patient (DEPLETHINK - LymphoDEPLEtion and THerapeutic Immunotherapy with NKR-2).
Date receipt dossier: 
18 nov 2019
EU record number: 
CYAD-N2T-005
EudraCT number: 
2018-000205-22
Pharmaceutical study code: 
NKR-2
Company / Sponsor: 
Celyad
Phase: 
I/II
Treated organism: 
Humans
Indication category: 
Cancer therapy
Disease: 
Different metastatic tumor type
Therapeutic approach: 
Immunotherapy
Genetic modification: 
NKG2D-chimeric antigen receptor
Method of transfer of nucleic acid of interest: 
Moloney Murine Leukemia Virus
Administered biological material: 
Autologous T cells retrovirally transduced with a chimeric antigen receptor based on the NKG2D receptor
Route of administration: 
Intravenous
Locations in Belgium: 
AZ Sint-Jan Brugge-Oostende AV, UZ Antwerpen, Institut Jules Bordet
Type of procedure: 
Contained use only
Current status: 
Authorized